CELLECTAR BIOSCIENCES INC (CLRB) Stock Price & Overview
NASDAQ:CLRB • US15117F8804
Current stock price
The current stock price of CLRB is 3.18 USD. Today CLRB is down by -2.15%. In the past month the price decreased by -6.74%. In the past year, price decreased by -71.27%.
CLRB Key Statistics
- Market Cap
- 13.483M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -10.29
- Dividend Yield
- N/A
CLRB Stock Performance
CLRB Stock Chart
CLRB Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to CLRB. When comparing the yearly performance of all stocks, CLRB is a bad performer in the overall market: 86.94% of all stocks are doing better.
CLRB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CLRB. CLRB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
CLRB Earnings
CLRB Forecast & Estimates
10 analysts have analysed CLRB and the average price target is 47.94 USD. This implies a price increase of 1407.55% is expected in the next year compared to the current price of 3.18.
CLRB Groups
Sector & Classification
CLRB Financial Highlights
Over the last trailing twelve months CLRB reported a non-GAAP Earnings per Share(EPS) of -10.29. The EPS increased by 72.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -145.48% | ||
| ROE | -219.69% | ||
| Debt/Equity | 0 |
CLRB Ownership
CLRB Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.9 | 364.65B | ||
| AMGN | AMGEN INC | 15.33 | 188.631B | ||
| GILD | GILEAD SCIENCES INC | 15.96 | 175.177B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.63 | 116.358B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.77 | 77.963B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 41.7 | 41.258B | ||
| INSM | INSMED INC | N/A | 31.039B | ||
| NTRA | NATERA INC | N/A | 28.733B | ||
| BIIB | BIOGEN INC | 11.41 | 26.917B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.64 | 23.098B | ||
| MRNA | MODERNA INC | N/A | 20.683B | ||
| EXAS | EXACT SCIENCES CORP | 341.89 | 19.837B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.676B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CLRB
Company Profile
Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. The company is headquartered in Florham Park, New Jersey and currently employs 11 full-time employees. The company went IPO on 2005-05-20. The firm is focused on the discovery, development, and commercialization of drugs for treatment of cancer. The Company, through its phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its lead programs are: Iopofosine I 131 (iopofosine), a beta-emitting iodine-131-based program which has been studied extensively; CLR 121225, an actinium-225-based program; and CLR 121125, an iodine-125 Auger-emitting program. Iopofosine evaluation is ongoing in a Phase IIb study in r/r multiple myeloma and central nervous system lymphoma patients and the CLOVER-2 Phase Ib study for pediatric patients with high grade gliomas.
Company Info
IPO: 2005-05-20
CELLECTAR BIOSCIENCES INC
100 Campus Drive
Florham Park NEW JERSEY 07932 US
CEO: JamesV.Caruso
Employees: 11
Phone: 16084418120
CELLECTAR BIOSCIENCES INC / CLRB FAQ
Can you describe the business of CELLECTAR BIOSCIENCES INC?
Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. The company is headquartered in Florham Park, New Jersey and currently employs 11 full-time employees. The company went IPO on 2005-05-20. The firm is focused on the discovery, development, and commercialization of drugs for treatment of cancer. The Company, through its phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its lead programs are: Iopofosine I 131 (iopofosine), a beta-emitting iodine-131-based program which has been studied extensively; CLR 121225, an actinium-225-based program; and CLR 121125, an iodine-125 Auger-emitting program. Iopofosine evaluation is ongoing in a Phase IIb study in r/r multiple myeloma and central nervous system lymphoma patients and the CLOVER-2 Phase Ib study for pediatric patients with high grade gliomas.
What is the stock price of CELLECTAR BIOSCIENCES INC today?
The current stock price of CLRB is 3.18 USD. The price decreased by -2.15% in the last trading session.
What is the dividend status of CELLECTAR BIOSCIENCES INC?
CLRB does not pay a dividend.
What is the ChartMill rating of CELLECTAR BIOSCIENCES INC stock?
CLRB has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How many employees does CELLECTAR BIOSCIENCES INC have?
CELLECTAR BIOSCIENCES INC (CLRB) currently has 11 employees.
What is CELLECTAR BIOSCIENCES INC worth?
CELLECTAR BIOSCIENCES INC (CLRB) has a market capitalization of 13.48M USD. This makes CLRB a Nano Cap stock.